RxDoctor Payments Data

Fuad Zayed, MD

Family Medicine · Alton, TXNPI 1356342190

Payments from drug & device makers

$2,322in general payments, 2019–2025

Across 102 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$344
  • Medtronic$235
  • Johnson & Johnson$210
  • Pfizer$206
  • AstraZeneca$152
  • plus $171 from 7 others

What the payments were for

  • Food & beverage$2,28999%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,322 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,735
Medicare patients
79
Services billed
1,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin378$503,979
OzempicSemaglutide282$365,421
Tresiba Flextouch U-200Insulin Degludec271$357,823
FarxigaDapagliflozin Propanediol212$252,207
RybelsusSemaglutide58$145,000
TrulicityDulaglutide88$126,794
TradjentaLinagliptin80$98,348
JanuviaSitagliptin Phosphate78$94,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$71,676
EliquisApixaban61$69,480
MyrbetriqMirabegron57$62,726
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$44,009
EntrestoSacubitril/Valsartan30$43,601
JanumetSitagliptin Phos/Metformin Hcl26$42,585
XareltoRivaroxaban37$35,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$49$607,640470 claims
Novo NordiskOzempic, Rybelsus$1,005$510,420340 claims
AstraZenecaFarxiga$152$252,207212 claims
Lilly USA, LLCTrulicity, Mounjaro$344$159,015108 claims
MerckJanuvia, Janumet$12$136,629104 claims
PfizerEliquis$206$69,48061 claims
NovartisEntresto$22$43,60130 claims
Johnson & JohnsonXarelto$210$35,53637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Alton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →